BAY-2686013

N/A

Report date: 2023/10/13 17:11:40
NME

Base Information

Drug NameBAY-2686013
Drug Alias NameBAY-2686013
ClassificationSmall molecules
Mechanisms of ActionPituitary adenylate cyclase-activating polypeptide type I receptor antagonists
TargetsPituitary adenylate cyclase-activating polypeptide type I receptor
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBayer AGNuvisan GmbhEvotec SE +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesNuvisan GmbhEvotec (UK) LtdBayer AG +[4] 
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A